Veintis™ is a bio-inspired vascular graft developed through tissue engineering which won the 2020 Chilean National Innovation Award.
Bioengineered vascular graft
8,138
Million USD, Global Vascular Graft Market by 2030
8.5
Million people with PAD in the US
5.4
Million people estimated to receive Renal Replacement Therapy in 2030
“Removing a vessel from the patient’s own body to use it in a different context has serious complications and is frankly absurd. Similarly, synthetic prostheses tend to fail quickly because of their propensity to generate thrombosis, hyperplasia, and infections. Veintis™ aims to be the best option on the market for patients requiring a vascular graft by offering personalized fit and bioinspired functionality.”
Juan Pablo Acevedo, Ph.D.
Director of the Tissue Engineering and Biofabrication R&D Division
Bioinspired by the macro and microstructure of human arteries. Veintis™ is the first reported tissue-engineered vascular graft (TEVG) that can be readily implanted after biofabrication and whose structure and fiber orientation mimics the tri-layered anatomy and the mechanical performance of human arteries. The number of layers, as well as the deposition angles and waviness of its fibers, were carefully determined so that the graft resembles the biomechanics of human vascular layers, which govern the mechanical behavior of vessels under cyclical blood pressure. Moreover, the unique biodesign of Veintis™ allows for the incorporation of cells. This cell-laden version of our product has proven to have an immunomodulatory function and to improve cell infiltration in vivo, thus providing clues to the potential resistance to inflammation and infection of the implant.
A proper, regenerative solution. Unlike synthetic alternatives, Veintis™ is manufactured with biomaterials and (optionally) stem cells to allow the formation of a natural tissue post-implantation. In Veintis™’ biodesign, we combine multiple regenerative biomaterials to let the patient’s own body naturally restore a new blood vessel. In other words, a definitive biological tissue is developed while the implant is biodegraded. This tissue remodeling capability has been tested and corroborated in large in vivo models and contrasted with the regenerative capacity of FDA-approved grafts and native vasculature (control). The histological results of this study demonstrate vast endothelialization and remodeling of the Veintis™ graft after six months.
Spearheading biofabrication of vascular grafts. The process from which Veintis™ is manufactured offers a revolutionary approach to ensuring patient access to superior grafts in terms of cost, personalization, and performance. This patented biofabrication approach, which combines robotics, automation, and regenerative medicine, allows for the production of a fully customized TEVG in a rapid and automated manner. It is a game-changer in our industry: while our competitor’s bioengineered vascular grafts take weeks to be suitable for implantation, our technology platform completes the production of a personalized bioengineered graft in less than two hours. We are encouraged by this edge and our vision for point-of-care fabrication through a revenue model that ensures the timely availability of bioengineered grafts for urgent and non-urgent procedures.
